NCT01157143View on ClinicalTrials.gov

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Peripheral Arterial Occlusive Disease
Interventions
DRUG

XRP0038 (NV1FGF)

"Pharmaceutical form : solution~Route of administration : intramuscular"

Trial Locations (2)

Unknown

Minneapolis

Bern

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY